In non-CNS diseases, high serum IL-6 levels have been correlated to poor survival of breast cancer [32], are thought to be proatherogenic [33], and are strong predictors of mortality in patients with end-stage renal disease [34]. The gene discussed is IL6; the disease is breast carcinoma.